STOCK TITAN

Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. has a significant shareholder group led by Farallon Capital Management, L.L.C., which reports beneficial ownership of 6,433,119 Shares of common stock. This position represents 9.99% of the company’s outstanding common stock.

The Farallon-managed funds collectively hold 6,348,906 Shares plus 1,500,000 Common Stock Purchase Warrants. Due to a 9.99% Beneficial Ownership Limitation in the warrant terms, only 84,213 Shares underlying the Warrants are currently counted toward beneficial ownership, with the remaining 1,415,787 Warrants treated as not exercisable within 60 days.

Positive

  • None.

Negative

  • None.
Beneficially owned Shares 6,433,119 Shares Shares of Protagonist Therapeutics common stock beneficially owned by the reporting persons
Ownership percentage 9.99% Percentage of Protagonist Therapeutics common stock class beneficially owned
Shares held directly 6,348,906 Shares Common Shares held by the Farallon funds before giving effect to Warrant exercises
Common Stock Purchase Warrants 1,500,000 Warrants Warrants held by the Farallon funds, each exercisable for one Share
Currently exercisable warrant shares 84,213 Shares Maximum Shares issuable on Warrant exercise under the 9.99% Beneficial Ownership Limitation
Non-counted Warrants 1,415,787 Warrants Warrants treated as not exercisable within 60 days for beneficial ownership purposes
Beneficial Ownership Limitation regulatory
"The terms of the Warrants provide that Warrants may not be exercised to the extent that... more than 9.99%... (the "Beneficial Ownership Limitation")."
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Common Stock Purchase Warrants financial
"1,500,000 Common Stock Purchase Warrants (the "Warrants"), each of which is exercisable..."
Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.
beneficially own regulatory
"the Reporting Persons would beneficially own, as determined in accordance with Section 13(d)..."
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
investment manager financial
"Farallon Capital Management, L.L.C.... is the investment manager of certain investment partnerships..."
Schedule 13G regulatory
"Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What stake in Protagonist Therapeutics (PTGX) does Farallon report in this Schedule 13G/A?

Farallon and related reporting persons report beneficial ownership of 6,433,119 Shares of Protagonist Therapeutics common stock, representing 9.99% of the outstanding Shares. This includes currently exercisable warrant shares, subject to a contractual Beneficial Ownership Limitation.

How many Protagonist Therapeutics (PTGX) shares and warrants do the Farallon funds hold?

The Farallon funds hold 6,348,906 Shares of PTGX common stock and 1,500,000 Common Stock Purchase Warrants. Each warrant is exercisable for one Share, but exercise is constrained by a 9.99% Beneficial Ownership Limitation in the warrant terms.

What is the 9.99% Beneficial Ownership Limitation disclosed for PTGX?

The Warrants held by the Farallon funds contain a 9.99% Beneficial Ownership Limitation, preventing exercise if it would cause beneficial ownership to exceed 9.99% of outstanding Shares. This cap restricts how many warrant shares can be included in Farallon’s reported ownership.

How many PTGX warrant shares can Farallon currently count as beneficially owned?

Under the Beneficial Ownership Limitation, the Farallon funds may currently exercise Warrants for up to 84,213 Shares. The remaining 1,415,787 Warrants are treated as not exercisable within 60 days and are excluded from the reported beneficial ownership calculation.

Who are the reporting persons in the Protagonist Therapeutics (PTGX) Schedule 13G/A Amendment No. 9?

The filing is made by Farallon Capital Management, L.L.C. as investment manager and multiple Farallon investment funds, plus several managing and senior managing members, collectively called the Farallon Individual Reporting Persons, with respect to the Shares and Warrants held by the Farallon funds.

Which entities benefit economically from Farallon’s PTGX holdings?

The Farallon Funds have the right to receive dividends and sale proceeds from the PTGX securities beneficially owned by the reporting persons. These investment partnerships are managed by Farallon Capital Management, L.L.C. and collectively hold the Shares and Warrants described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





74366E102

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/13/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/13/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026

Comments accompanying signature: Each of Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C, and Farallon Healthcare Partners (GP), L.L.C. has executed this statement in Mill Valley, California, on behalf of itself and each fund for which it is the general partner.
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)